Trump's insistence on getting treatments approved before Nov. is based on politics, not research, and coming after other recent instances of federal-health officials capitulating to him, , has vaccine experts deeply worried. Bruce Gellin, the president of global immunization at the Sabin Vaccine Institutesyas: “despite reassurances that moving at warp speed won’t cut corners, if FDA’s gold standard of data-driven decision making can be trumped by politics, then I worry about how confident Americans will be about any product that the FDA approves.’’This is hardly a theoretical concern. On Monday, the Financial Times reported that the Trump Administration is “considering bypassing normal US regulatory standards” to approve an experimental British vaccine for use in this country before the election. If that happens, the F.D.A. will risk losing its hard-won credibility for good."